{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:39:53Z","timestamp":1791841193678,"version":"4.3.4"},"reference-count":75,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Janus kinase (JAK) inhibitors are effective oral therapies for inflammatory bowel disease (IBD). While acne is a known adverse event in dermatological cohorts, its incidence and risk factors in the IBD population are not well-defined. We aimed to determine the pooled incidence of acne in IBD patients treated with JAK inhibitors and to explore this risk across key clinical subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a systematic review and meta-analysis following PRISMA guidelines. MEDLINE, EMBASE, and CENTRAL were searched from inception to September 2025 for randomized controlled trials (RCTs) and observational studies reporting acne incidence in IBD patients on JAK inhibitors. Data were pooled using a random-effects generalized linear mixed-effects model. Pre-specified subgroup analyses were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 50 studies (5 RCTs, 45 observational) involving 9902 IBD patients were included. The overall pooled incidence of acne was 8.6% (95% CI: 6.4%-11.6%). Acne rates were significantly higher (P &amp;lt; .0001) with the upadacitinib (12.2%), compared to tofacitinib (2.6%) and filgotinib (2.3%). A numerically higher incidence was observed during induction (8.6%) versus maintenance (4.2%) therapy, though this difference was not statistically significant (P = .07). The incidence was significantly higher in the pediatric population (12.2%) compared to adults (7.4%) (P = .03). In RCTs, JAK inhibitors were associated with significantly increased odds of acne compared to placebo (OR 2.43, 95% CI: 1.33-4.43, P = .019). No statistically significant difference was observed by IBD subtype.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Acne is a common adverse event in IBD patients treated with JAK inhibitors. The reported incidence of acne was significantly higher with upadacitinib, in the pediatric population, and numerically higher during the induction phase of treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izag032","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T12:46:55Z","timestamp":1770814015000},"page":"1800-1814","source":"Crossref","is-referenced-by-count":4,"title":["Incidence of acne in patients with inflammatory bowel disease treated with Janus kinase inhibitors: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1673-7792","authenticated-orcid":false,"given":"Mohammed Nabil","family":"Quraishi","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Sheikh Shakhbout Medical City, Pure Health , Abu Dhabi,","place":["United Arab Emirates"]},{"name":"Institute of Cancer and Genomic Sciences, University of Birmingham , Birmingham,","place":["United Kingdom"]},{"name":"College of Medicine and Health Sciences, Khalifa University of Science and Technology , Abu Dhabi,","place":["United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam A","family":"Alahmad","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sheikh Shakhbout Medical City, Pure Health , Abu Dhabi,","place":["United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thaer Khaleel","family":"Swaid","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sheikh Shakhbout Medical City, Pure Health , Abu Dhabi,","place":["United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Facciorusso","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Department of Experimental Medicine, Universit\u00e0 del Salento , Lecce,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa A","family":"Grimshaw","sequence":"additional","affiliation":[{"name":"Harvey Cushing\/John Hay Whitney Medical Library, Yale University , New Haven, CT,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3905-2903","authenticated-orcid":false,"given":"Badr","family":"Al-Bawardy","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, King Faisal Specialist Hospital and Research Center , Riyadh,","place":["Saudi Arabia"]},{"name":"Department of Internal Medicine, Section of Digestive Diseases, Yale School of Medicine , New Haven, CT,","place":["United States"]},{"name":"College of Medicine, Alfaisal University , Riyadh,","place":["Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"key":"2026090114021770000_izag032-B1","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1056\/NEJMra0804647","article-title":"Inflammatory bowel disease","volume":"361","author":"Abraham","year":"2009","journal-title":"N Engl J Med"},{"key":"2026090114021770000_izag032-B2","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"2026090114021770000_izag032-B3","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1136\/flgastro-2023-102400","article-title":"JAK inhibitors for inflammatory bowel disease: recent advances","volume":"15","author":"Honap","year":"2024","journal-title":"Frontline Gastroenterol"},{"key":"2026090114021770000_izag032-B4"},{"key":"2026090114021770000_izag032-B5","doi-asserted-by":"publisher","first-page":"e129","DOI":"10.1016\/S2665-9913(24)00033-X","article-title":"JAK inhibitors\u2014friend or foe?","volume":"6","author":"Rheumatology","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"2026090114021770000_izag032-B6","doi-asserted-by":"publisher","first-page":"2397477","DOI":"10.1080\/09546634.2024.2397477","article-title":"Janus kinase inhibitors and adverse events of acne in dermatologic indications: a systematic review and network meta-analysis","volume":"35","author":"Chen","year":"2024","journal-title":"J Dermatol Treat"},{"key":"2026090114021770000_izag032-B7","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1001\/jamadermatol.2023.3830","article-title":"Janus kinase inhibitors and adverse events of acne: a systematic review and meta-analysis","volume":"159","author":"Martinez","year":"2023","journal-title":"JAMA Dermatol"},{"key":"2026090114021770000_izag032-B8","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1080\/1744666X.2023.2214728","article-title":"The evolving role of JAK inhibitors in the treatment of inflammatory bowel disease","volume":"19","author":"Gupta","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"key":"2026090114021770000_izag032-B9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.14309\/ajg.0000000000003119","article-title":"Drug-induced acne in inflammatory bowel disease: a practical guide for the gastroenterologist","volume":"120","author":"Temido","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"2026090114021770000_izag032-B10","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026090114021770000_izag032-B11","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/2046-4053-1-2","article-title":"The nuts and bolts of PROSPERO: an international prospective register of systematic reviews","volume":"1","author":"Booth","year":"2012","journal-title":"Syst Rev"},{"key":"2026090114021770000_izag032-B12","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","article-title":"PRESS peer review of electronic search strategies: 2015 guideline statement","volume":"75","author":"McGowan","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"2026090114021770000_izag032-B13","year":"2021"},{"key":"2026090114021770000_izag032-B14","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2026090114021770000_izag032-B15","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"2026090114021770000_izag032-B16","author":"Wells"},{"key":"2026090114021770000_izag032-B17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Based Mental Health"},{"key":"2026090114021770000_izag032-B18","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"2026090114021770000_izag032-B19","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/jnci\/22.4.719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"Mantel","year":"1959","journal-title":"J Natl Cancer Inst"},{"key":"2026090114021770000_izag032-B20","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"2026090114021770000_izag032-B21","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"2026090114021770000_izag032-B22","doi-asserted-by":"crossref","DOI":"10.4159\/9780674040243","volume-title":"Summing Up: The Science of Reviewing Research","author":"Light","year":"1984"},{"key":"2026090114021770000_izag032-B23","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib induction and maintenance therapy for Crohn\u2019s disease","volume":"388","author":"Loftus","year":"2023","journal-title":"N Engl J Med"},{"key":"2026090114021770000_izag032-B24","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"key":"2026090114021770000_izag032-B25","doi-asserted-by":"publisher","first-page":"jjaf080","DOI":"10.1093\/ecco-jcc\/jjaf080","article-title":"Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn\u2019s disease and ulcerative colitis","volume":"19","author":"D\u2019Haens","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026090114021770000_izag032-B26","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.14309\/ajg.0000000000002635","article-title":"Tofacitinib in Acute Severe Ulcerative Colitis (TACOS): a randomized controlled trial","volume":"119","author":"Singh","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"2026090114021770000_izag032-B27","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1093\/ecco-jcc\/jjad153","article-title":"Tofacitinib versus oral prednisolone for induction of remission in moderately active ulcerative colitis [ORCHID]: a prospective, open-label, randomized, pilot study","volume":"18","author":"Singh","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026090114021770000_izag032-B28","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.cgh.2023.08.021","article-title":"Comparative effectiveness of upadacitinib vs ustekinumab for ulcerative colitis: a multicenter retrospective cohort study","volume":"22","author":"Dalal","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026090114021770000_izag032-B29","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/apt.18406","article-title":"Comparative efficacy and safety of three janus kinase inhibitors in ulcerative colitis: a real-world multicentre study in Japan","volume":"61","author":"Akiyama","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"2026090114021770000_izag032-B30","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1093\/ibd\/izaf115","article-title":"Incidence and risk factors for development of acne (JAKne) in patients with inflammatory bowel disease treated with upadacitinib","volume":"31","author":"Choi","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2026090114021770000_izag032-B31","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1093\/ecco-jcc\/jjaa075","article-title":"Real-world effectiveness of tofacitinib for moderate to severe ulcerative colitis: a multicentre UK experience","volume":"14","author":"Honap","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2026090114021770000_izag032-B32","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.1007\/s10620-024-08630-3","article-title":"Response to upadacitinib in patients with inflammatory bowel disease previously treated with tofacitinib","volume":"69","author":"Odah","year":"2024","journal-title":"Dig Dis Sci"},{"key":"2026090114021770000_izag032-B33","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1007\/s10620-022-07444-5","article-title":"Tofacitinib appears well tolerated and effective for the treatment of patients with refractory Crohn\u2019s disease","volume":"67","author":"Lee","year":"2022","journal-title":"Dig Dis Sci"},{"key":"2026090114021770000_izag032-B34","doi-asserted-by":"publisher","first-page":"jjae182","DOI":"10.1093\/ecco-jcc\/jjae182","article-title":"Upadacitinib for induction of remission in pediatric ulcerative colitis: an international multicenter study","volume":"19","author":"Yerushalmy-Feler","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026090114021770000_izag032-B35","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/apt.70246","article-title":"Azathioprine or tofacitinib as maintenance therapy in corticosteroid-responsive acute severe ulcerative colitis","volume":"62","author":"Singh","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"2026090114021770000_izag032-B36","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/jpn3.12408","article-title":"Upadacitinib is associated with clinical response and steroid-free remission for children and adolescents with inflammatory bowel disease","volume":"80","author":"Runde","year":"2025","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2026090114021770000_izag032-B37","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/MCG.00000000000021572025","article-title":"Upadacitinib results in endoscopic remission in patients with inflammatory bowel disease and prior tofacitinib failure","volume":"59","author":"Lee","year":"2025","journal-title":"J Clin Gastroenterol"},{"key":"2026090114021770000_izag032-B38","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3390\/biomedicines13010190","article-title":"An analysis of the effectiveness and safety of upadacitinib in the treatment of inflammatory bowel disease: a multicenter real-world study","volume":"13","author":"Wu","year":"2025","journal-title":"Biomedicines"},{"key":"2026090114021770000_izag032-B39","doi-asserted-by":"publisher","first-page":"7804","DOI":"10.3390\/jcm13247804","article-title":"Real-world effectiveness and safety of selective JAK inhibitors in ulcerative colitis and Crohn\u2019s disease: a retrospective, multicentre study","volume":"13","author":"Farkas","year":"2024","journal-title":"J Clin Med"},{"key":"2026090114021770000_izag032-B40","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1136\/flgastro-2024-102668","article-title":"Real-world effectiveness of upadacitinib in Crohn\u2019s disease: a UK multicentre retrospective cohort study","volume":"15","author":"Elford","year":"2024","journal-title":"Frontline Gastroenterol"},{"key":"2026090114021770000_izag032-B41","doi-asserted-by":"publisher","first-page":"464","DOI":"10.5217\/ir.2024.00148","article-title":"Propensity score-matched real-world comparative treatment outcomes of Janus kinase inhibitors for ulcerative colitis in patients with and without prior exposure to anti-tumor necrosis factor \u03b1 antibody","volume":"23","author":"Ikenouchi","year":"2025","journal-title":"Intest Res"},{"key":"2026090114021770000_izag032-B42","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1093\/ibd\/izad135","article-title":"Real-life efficacy of tofacitinib in various situations in ulcerative colitis: a retrospective worldwide multicenter collaborative study","volume":"30","author":"Res\u00e1l","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2026090114021770000_izag032-B43","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.cgh.2025.07.042","article-title":"Real-world Experience of Upadacitinib Reinduction and High-dose Maintenance Therapy in Inflammatory Bowel Disease","volume":"24","author":"Ho","year":"2026","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026090114021770000_izag032-B44","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1111\/apt.70016","article-title":"Upadacitinib for induction of remission in paediatric Crohn\u2019s disease: an international multicentre retrospective study","volume":"61","author":"Cohen","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"2026090114021770000_izag032-B45","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1016\/s0016-5085(24)03783-1","article-title":"Real-world effectiveness and safety of upadacitinib in Crohn\u2019s Disease: a multicenter study","volume":"23","author":"Devi","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026090114021770000_izag032-B46","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1016\/j.cgh.2023.03.001","article-title":"Upadacitinib is effective and safe in both ulcerative colitis and Crohn\u2019s disease: prospective real-world experience","volume":"21","author":"Friedberg","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026090114021770000_izag032-B47","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1016\/j.cgh.2020.06.050","article-title":"Safety of tofacitinib in a real-world cohort of patients with ulcerative colitis","volume":"19","author":"Deepak","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026090114021770000_izag032-B48","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1186\/s12876-024-03341-5","article-title":"Real world evidence on the effectiveness and safety of tofacitinib in ulcerative colitis in Lebanon","volume":"24","author":"Sharara","year":"2024","journal-title":"BMC Gastroenterol"},{"key":"2026090114021770000_izag032-B49","doi-asserted-by":"publisher","first-page":"95","DOI":"10.5217\/ir.2024.00187","article-title":"Comparative short-term efficacy of upadacitinib versus tofacitinib for ulcerative colitis: a 24-week real-world study in Japan","volume":"24","author":"Tamura","year":"2026","journal-title":"Intest Res"},{"key":"2026090114021770000_izag032-B50","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1111\/apt.70073","article-title":"Effectiveness and safety of upadacitinib induction therapy for 223 patients with Crohn\u2019s disease: A GETAID multicentre cohort study","volume":"61","author":"Richard","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"2026090114021770000_izag032-B51","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.cgh.2025.04.031","article-title":"Janus Kinase (JAK) inhibitor-induced acne in inflammatory bowel disease: an international, multicenter, retrospective cohort study","volume":"24","author":"Honap","year":"2026","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026090114021770000_izag032-B52","doi-asserted-by":"publisher","first-page":"347","DOI":"10.5217\/ir.2024.00127","article-title":"Upadacitinib induction is effective and safe in ulcerative colitis patients including those with prior exposure to tofacitinib: a multicenter real-world cohort study","volume":"23","author":"Gilmore","year":"2025","journal-title":"Intest Res"},{"key":"2026090114021770000_izag032-B53","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/apt.70199","article-title":"Effectiveness and safety of a second JAK inhibitor in ulcerative colitis: the J2J multicentre study","volume":"62","author":"Osty","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"2026090114021770000_izag032-B54","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.cgh.2025.07.025","article-title":"Comparative Effectiveness of Tofacitinib vs Upadacitinib for the Treatment of Acute Severe Ulcerative Colitis","volume":"24","author":"Honap","year":"2026","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026090114021770000_izag032-B55","doi-asserted-by":"publisher","first-page":"i1340","DOI":"10.1093\/ecco-jcc\/jjad212.0848","article-title":"Observational real-world evidence on the efficacy and safety of Janus Kinase inhibitors (JAKi) in the treatment of moderate to severe Active Ulcerative Colitis (UC)","volume":"18","author":"Al-Zarrad","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026090114021770000_izag032-B56","doi-asserted-by":"publisher","first-page":"i1962","DOI":"10.1093\/ecco-jcc\/jjae190.1237","article-title":"Impact of upadacitinib in Crohn\u2019s disease in the medium term: results from the UPITA-Crohn registry in clinical practice","volume":"19","author":"Caballero Mateos","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026090114021770000_izag032-B57","doi-asserted-by":"publisher","first-page":"i1917","DOI":"10.1093\/ecco-jcc\/jjad212.1202","article-title":"Upadacitinib appears effective in inducing clinical, biochemical, endoscopic and histologic improvements in previously treatment refractory Ulcerative Colitis","volume":"18","author":"Choon","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026090114021770000_izag032-B58","doi-asserted-by":"publisher","first-page":"i2194","DOI":"10.1093\/ecco-jcc\/jjad212.1379","article-title":"N07 JAKne: JAK inhibitor associated acne, a real-life single-center experience","volume":"18","author":"De Dycker","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026090114021770000_izag032-B59","doi-asserted-by":"publisher","first-page":"i1898","DOI":"10.1093\/ecco-jcc\/jjae190.1203","article-title":"Janus kinase inhibitors for the management of acute severe ulcerative colitis: a multicentre study","volume":"19","author":"Gilmore","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026090114021770000_izag032-B60","first-page":"A122","article-title":"4CPS-183 Multicentre study: evaluation of the effectiveness and safety of upadacitinib in inflammatory bowel disease","volume":"32","author":"Balazote","year":"2025","journal-title":"Eur J Hosp Pharm"},{"key":"2026090114021770000_izag032-B61","doi-asserted-by":"crossref","first-page":"i1709","DOI":"10.1093\/ecco-jcc\/jjae190.1079","article-title":"Incidence, risk factors, and management of acne in IBD patients on JAK Inhibitors: A multicentre retrospective cohort study (The JAKNE Project)","volume":"19","author":"Gonzalez Lama","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026090114021770000_izag032-B62","doi-asserted-by":"publisher","first-page":"i2116","DOI":"10.1093\/ecco-jcc\/jjae190.1333","article-title":"New onset acne reported in the majority of patients with upadacitinib-treated Inflammatory Bowel Disease","volume":"19","author":"Omrani","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026090114021770000_izag032-B63","doi-asserted-by":"publisher","first-page":"i1747","DOI":"10.1093\/ecco-jcc\/jjae190.1105","article-title":"Induction treatment with upadacitinib is associated with high rate of clinical response in patients with refractory Inflammatory Bowel Disease","volume":"19","author":"Kitsou","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026090114021770000_izag032-B64","doi-asserted-by":"publisher","first-page":"i1721","DOI":"10.1093\/ecco-jcc\/jjae190.1089","article-title":"Real-life experience with Upadacitinib in Crohn\u2019s disease (UPARECOL-CD Induction): A Colombian cohort","volume":"19","author":"Parra Izquierdo","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026090114021770000_izag032-B65","doi-asserted-by":"publisher","first-page":"i1773","DOI":"10.1093\/ecco-jcc\/jjae190.1123","article-title":"Long term real-world effectiveness and safety of upadacitinib in patients with moderate to severe Crohn\u2019s disease: A Belgian multi-centric refractory cohort","volume":"19","author":"Pavlidi","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026090114021770000_izag032-B66","doi-asserted-by":"publisher","first-page":"i1235","DOI":"10.1093\/ecco-jcc\/jjae190.0800","article-title":"One year outcomes of upadacitinib in Crohn\u2019s disease in a large real-world cohort","volume":"19","author":"Ramos Belinchon","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026090114021770000_izag032-B67","doi-asserted-by":"publisher","first-page":"i1246","DOI":"10.1093\/ecco-jcc\/jjae190.0807","article-title":"Real world outcomes of Upadacitinib induction therapy for patient with inflammatory bowel disease in Korea","volume":"19","author":"Ye","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026090114021770000_izag032-B68","doi-asserted-by":"publisher","first-page":"S936","DOI":"10.14309\/01.ajg.0001034600.37922.a6","article-title":"Treatment outcomes of prolonged induction or re-escalation dosing of upadacitinib in patients with inflammatory bowel disease","volume":"119","author":"Axenfeld","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"2026090114021770000_izag032-B69","doi-asserted-by":"publisher","first-page":"S940","DOI":"10.14309\/01.ajg.0001034620.71782.d3","article-title":"Recapturing response and remission with short-term upadacitinib dose escalation","volume":"119","author":"Golla","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"2026090114021770000_izag032-B70","doi-asserted-by":"crossref","first-page":"i1834","DOI":"10.1093\/ecco-jcc\/jjae190.1162","article-title":"Dose-Dependent incidence of acne in Korean patients treated with upadacitinib","volume":"19","author":"Lee","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026090114021770000_izag032-B71","doi-asserted-by":"publisher","first-page":"i1045","DOI":"10.1093\/ecco-jcc\/jjad212.0665","article-title":"Effectiveness of upadacitinib in patients with Ulcerative Colitis: a real-life, multicenter, Italian report","volume":"18","author":"Teani","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026090114021770000_izag032-B72","author":"Rahimi","year":"2025"},{"key":"2026090114021770000_izag032-B73","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2165\/11588900-000000000-00000","article-title":"Drug-induced acneiform eruption","volume":"12","author":"Du-Thanh","year":"2011","journal-title":"Am J Clin Dermatol"},{"key":"2026090114021770000_izag032-B74","doi-asserted-by":"crossref","first-page":"e350","DOI":"10.1111\/ijd.17435","article-title":"Characterization and clinical outcomes of JAK inhibitor-associated acne (JAK-acne) in patients with alopecia areata treated with tofacitinib: a single-center retrospective study","volume":"63","author":"Huang","year":"2024","journal-title":"Int J Dermatol"},{"key":"2026090114021770000_izag032-B75","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jdin.2025.04.003","article-title":"History of acne is associated with new-onset acne development in patients with alopecia areata treated with Janus kinase inhibitors","volume":"21","author":"Gordon","year":"2025","journal-title":"JAAD Int"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/9\/1800\/67241688\/izag032.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/9\/1800\/67241688\/izag032.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T18:02:23Z","timestamp":1788285743000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/32\/9\/1800\/8507036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":75,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,3,5]]},"published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izag032","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,3,5]]}}}